Presentation is loading. Please wait.

Presentation is loading. Please wait.

Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma 

Published byMiluše Bílková Modified over 5 years ago

Similar presentations

Presentation on theme: "Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma "— Presentation transcript:

1 Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma  Hestia Mellert, Trudi Foreman, Leisa Jackson, Dianna Maar, Scott Thurston, Kristina Koch, Amanda Weaver, Samantha Cooper, Nicholas Dupuis, Ubaradka G. Sathyanarayana, Jakkie Greer, Westen Hahn, Dawne Shelton, Paula Stonemetz, Gary A. Pestano  The Journal of Molecular Diagnostics  Volume 19, Issue 3, Pages (May 2017) DOI: /j.jmoldx Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

2 Figure 1 Precision testing. A: Assays for genetic variants were evaluated by Droplet Digital (dd) PCR (Bio-Rad, Pleasanton, CA) at Horizon Discovery (Cambridge, UK) with a prequalified standard of known percent minor variant frequencies (%MVF). The same standards were evaluated at Biodesix, Inc. (Boulder, CO) using the QX200 ddPCR system (Bio-Rad). EML4-ALK was not evaluated in the study. B: Intrarun studies for each EGFR and KRAS variant were run with three plasma samples from donors with cancer or, in the case of L858R, using analytical cell line standards (Horizon Discovery). C: Intrarun studies for the EML4-ALK multiplexed assay was run with three concentrations of analytical RNA standard. D: Inter-run studies of EGFR and KRAS were performed as in B. E: Interday testing of the EML-ALK assay was performed as in C. Data are expressed as means ± SD. n = 3 (B and C, independent runs; D and E, consecutive days of testing). Med., medium. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

3 Figure 2 Robustness testing. Analytical positive control was spiked into normal human plasma, extracted, and tested by Droplet Digital PCR (Bio-Rad, Pleasanton, CA) over 21 consecutive business days. Both mutant (MUT) and wild-type (WT) copies are reported. A: EGFR variants ΔE746-A750, L858R, and T790M. B: KRAS variants G12C, G12D, and G12V. C: EML4-ALK fusion copies and control gene copies detected using the EML4-ALK multiplex for the detection of variants 1, 2, and 3. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

4 Figure 3 Sensitivity and specificity clinical validation studies. Validation samples with reference result and Droplet Digital (dd) PCR (Bio-Rad, Pleasanton, CA) result, along with associated sensitivity, specificity, and concordance calculations (left) and an example of a two-dimensional plot of results not detected and detected from each validation set (right) are shown for EGFR variants ΔE746-A750 (A), L858R (B), and T790M (C); KRAS variants G12C (D), G12D (E), and G12V (F); and EML4-ALK multiplex for the detection of variants 1, 2, and 3 (G). ∗Prevalence of EML4-ALK variants 1, 2, and 3 represents that 78.4% of the total ALK mutations were used to calculate sensitivity and concordance. WT, wild type. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

5 Figure 4 Assay utilization by ordering physicians. A: Workflow overview of the CLIA-certified laboratory test (Biodesix, Inc., Boulder, CO). The test process is initiated when whole blood is drawn into two blood-collection tubes (BCT; Streck, La Vista, NE) and the collection kit arrives at the centralized CLIA laboratory. Patient samples are accessioned into the Laboratory Information Management System (LIMS) and processed through parallel workflows to isolate either cDNA or RNA. Following nucleic acid extraction (and cDNA synthesis for RNA), samples are processed using the QX200 Droplet Digital (dd) PCR system (Bio-Rad, Pleasanton, CA). Droplet count evaluation is conducted using QuantaSoft version (Bio-Rad), and test result reports are generated from the secure LIMS. B: The percentages of orders submitted from physicians affiliated with community, academic, and government-run centers. Undefined represents those centers for which information was not provided with the sample. C: The percentage of test result reports with an individual variant, that variant with at least one other variant, and the variant as one of a full set of seven. cfDNA, circulating free DNA. The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx ) Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Download ppt "Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma "

Similar presentations

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.
Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer R. Zhang, R. Peng, Z. Li, P.

Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer R. Zhang, R. Peng, Z. Li, P.
Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.
Genes with Bimodal Expression Are Robust Diagnostic Targets that Define Distinct Subtypes of Epithelial Ovarian Cancer with Different Overall Survival 

Genes with Bimodal Expression Are Robust Diagnostic Targets that Define Distinct Subtypes of Epithelial Ovarian Cancer with Different Overall Survival 
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,
Carol Beadling, Tanaya L. Neff, Michael C

Carol Beadling, Tanaya L. Neff, Michael C
Validation of a Commercially Available Screening Tool for the Rapid Identification of CGG Trinucleotide Repeat Expansions in FMR1  Grace X.Y. Lim, Yu.

Validation of a Commercially Available Screening Tool for the Rapid Identification of CGG Trinucleotide Repeat Expansions in FMR1  Grace X.Y. Lim, Yu.
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.
Emily M. Kudalkar, Naif A. M

Emily M. Kudalkar, Naif A. M
Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients  Marica Grskovic, David J. Hiller, Lane.

Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients  Marica Grskovic, David J. Hiller, Lane.
Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA  Christina Wood-Bouwens, Billy T. Lau, Christine.

Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA  Christina Wood-Bouwens, Billy T. Lau, Christine.
A Comparison of Cell-Free DNA Isolation Kits

A Comparison of Cell-Free DNA Isolation Kits
Mark G. Erlander, Xiao-Jun Ma, Nicole C

Mark G. Erlander, Xiao-Jun Ma, Nicole C
A Comparison of Cell-Free DNA Isolation Kits

A Comparison of Cell-Free DNA Isolation Kits
A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer  Maruja E. Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui.

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer  Maruja E. Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui.
Suppression of Wild-Type Amplification by Selectivity Enhancing Agents in PCR Assays that Utilize SuperSelective Primers for the Detection of Rare Somatic.

Suppression of Wild-Type Amplification by Selectivity Enhancing Agents in PCR Assays that Utilize SuperSelective Primers for the Detection of Rare Somatic.
Detection of HIV-1 Minority Variants Containing the K103N Drug-Resistance Mutation Using a Simple Method to Amplify RNA Targets (SMART)  Kenneth Morabito,

Detection of HIV-1 Minority Variants Containing the K103N Drug-Resistance Mutation Using a Simple Method to Amplify RNA Targets (SMART)  Kenneth Morabito,
High-Fidelity DNA Polymerase Enhances the Sensitivity of a Peptide Nucleic Acid Clamp PCR Assay for K-ras Mutations  Bjørnar Gilje, Reino Heikkilä, Satu.

High-Fidelity DNA Polymerase Enhances the Sensitivity of a Peptide Nucleic Acid Clamp PCR Assay for K-ras Mutations  Bjørnar Gilje, Reino Heikkilä, Satu.
Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR  Jennifer.

Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR  Jennifer.

Similar presentations

Ads by Google